Literature DB >> 8001023

Effect of murine interferon alpha/beta on tumour-induced suppressor function.

D M Sahasrabudhe1, J C Dusel.   

Abstract

T-lymphocyte-mediated immunosuppression has been described in several animal models and in man. In animal models. T-cell-mediated immunosuppression can hasten the development of cancers, permit the growth of tumors in immunocompetent hosts, and inhibit otherwise effective antitumor immunotherapy. Cyclophosphamide can abrogate the T-cell-mediated immunosuppression. However, inappropriately administered cyclophosphamide can adversely affect antitumor immunity. On the basis of data showing that interferon alpha/beta (IFN alpha/beta) and IFN beta selectively abrogate the T-cell-mediated dinitrofluorobenzene-specific suppressor function, we investigated the efficacy of purified murine IFN alpha/beta in manipulating tumor-induced T-cell-mediated immunosuppression in the well-characterized P815 mastocytoma model. In this model, generation of cytotoxicity in vitro and its inhibition by T cells correlates with antitumor immunity in vivo. We report that IFN alpha/beta selectively diminishes the generation of tumor-induced suppressor activity.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8001023     DOI: 10.1007/BF01534422

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  31 in total

Review 1.  Xenogeneic monoclonal antibodies to mouse lymphoid differentiation antigens.

Authors:  J A Ledbetter; L A Herzenberg
Journal:  Immunol Rev       Date:  1979       Impact factor: 12.988

2.  Establishment and functional analysis of a cloned, antigen-specific suppressor effector T cell line.

Authors:  H Nakauchi; I Ohno; M Kim; K Okumura; T Tada
Journal:  J Immunol       Date:  1984-01       Impact factor: 5.422

3.  A cloned T-cell line from a tolerant mouse represents a novel antigen-specific suppressor cell type.

Authors:  J Heuer; K Brüner; B Opalka; E Kölsch
Journal:  Nature       Date:  1982-04-01       Impact factor: 49.962

4.  Effects of cytotoxic monoclonal antibody specific for T200 glycoprotein on functional lymphoid cell populations.

Authors:  G Dennert; R Hyman; J Lesley; I S Trowbridge
Journal:  Cell Immunol       Date:  1980-08-01       Impact factor: 4.868

Review 5.  Preclinical biology of alpha interferons.

Authors:  P P Trotta
Journal:  Semin Oncol       Date:  1986-09       Impact factor: 4.929

6.  Defining protective responses to pathogens: cytokine profiles in leprosy lesions.

Authors:  M Yamamura; K Uyemura; R J Deans; K Weinberg; T H Rea; B R Bloom; R L Modlin
Journal:  Science       Date:  1991-10-11       Impact factor: 47.728

7.  Characterization of a cloned ultraviolet radiation (UV)-induced suppressor T cell line that is capable of inhibiting anti-UV tumor-immune responses.

Authors:  L K Roberts
Journal:  J Immunol       Date:  1986-03-01       Impact factor: 5.422

8.  HLA-DR synthesis induction and expression in HLA-DR-negative carcinoma cell lines of diverse origins by interferon-gamma but not by interferon-beta.

Authors:  A R Shaw; J K Chan; S Reid; J Seehafer
Journal:  J Natl Cancer Inst       Date:  1985-06       Impact factor: 13.506

9.  Immunoregulatory pathways in adult responder mice. III. Establishment of a GAT-specific suppressor T cell clone from GAT-tolerant responders which afferently regulates DTH responses.

Authors:  M K Jenkins; S D Miller
Journal:  J Mol Cell Immunol       Date:  1985

10.  Radiation-induced, immunologically mediated regression of an established tumor as an example of successful therapeutic immunomanipulation. Preferential elimination of suppressor T cells allows sustained production of effector T cells.

Authors:  R J North
Journal:  J Exp Med       Date:  1986-11-01       Impact factor: 14.307

View more
  2 in total

1.  Failure of tumor-reactive lymph node cells to kill tumor in the presence of immune-suppressive CD34+ cells can be overcome with vitamin D3 treatment to diminish CD34+ cell levels.

Authors:  K Wiers; M A Wright; K Vellody; M R Young
Journal:  Clin Exp Metastasis       Date:  1998-04       Impact factor: 5.150

2.  The Use of Registries to Improve Cancer Treatment: A National Database for Patients Treated with Interleukin-2 (IL-2).

Authors:  Howard L Kaufman; Michael K Wong; Gregory A Daniels; David F McDermott; Sandra Aung; James N Lowder; Michael A Morse
Journal:  J Pers Med       Date:  2014-03-07
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.